![Usefulness of [ 68 Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [ 18 F]FDG PET/CT findings](https://sofie.com/wp-content/uploads/2021/04/Usefulness-of-68-GaGa-DOTA-FAPI-04-PETCT-in-patients-presenting-with-inconclusive-18-FFDG-PETCT-findings.png)
FDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer’s Disease
“This FDA approval signals another important advancement in the evaluation of Alzheimer’s Disease. With […]
A Message from our CEO, Patrick Phelps
With cases of COVID-19 spreading throughout the world and America, healthcare workers are on […]
Sofie Biosciences Enters Strategic Collaboration For The Production And Distribution Of FAPI Precursors
LOS ANGELES and RADEBERG, Germany, Oct. 10, 2019 /PRNewswire/ — Sofie Biosciences, Inc. (SOFIE), a Theranostics company, announced […]
SOFIE Co-Founder, President and CEO Patrick Phelps one of Biocom’s Life Science Catalyst Award Winners
From Biocom:
SAN DIEGO–Biocom, the association representing the California life science industry, today […]
SOFIE Signs Lease for East Coast Office to Better Support Customers
Dulles, VA, September 4th, 2019, – SOFIE Inc. (SOFIE), a Theranostics company, is furthing […]
SOFIE’s IP Named FAPI Wins SNMMI 2019 Image of The Year
SNMMI 2019 Image of the Year: 68Ga-FAPI-PET/CT in patients reflecting 12 different tumor entities. […]
SOFIE Breaks Ground On 30,000 Sq Ft Theranostic Center Of Excellence
TOTOWA, N.J., June 24, 2019 /PRNewswire/ — SOFIE Inc. (SOFIE), a Theranostics company headquartered in Los Angeles, CA, […]